Takeda Pharmaceutical Company Statistics
Total Valuation
Takeda Pharmaceutical Company has a market cap or net worth of JPY 6.40 trillion. The enterprise value is 11.15 trillion.
Market Cap | 6.40T |
Enterprise Value | 11.15T |
Important Dates
The next estimated earnings date is Thursday, January 30, 2025.
Earnings Date | Jan 30, 2025 |
Ex-Dividend Date | Mar 28, 2025 |
Share Statistics
Takeda Pharmaceutical Company has 1.59 billion shares outstanding. The number of shares has increased by 1.07% in one year.
Current Share Class | n/a |
Shares Outstanding | 1.59B |
Shares Change (YoY) | +1.07% |
Shares Change (QoQ) | +1.29% |
Owned by Insiders (%) | 0.06% |
Owned by Institutions (%) | 47.54% |
Float | 1.58B |
Valuation Ratios
The trailing PE ratio is 22.19 and the forward PE ratio is 37.03. Takeda Pharmaceutical Company's PEG ratio is 3.95.
PE Ratio | 22.19 |
Forward PE | 37.03 |
PS Ratio | 1.40 |
PB Ratio | 0.92 |
P/TBV Ratio | n/a |
P/FCF Ratio | 9.44 |
P/OCF Ratio | n/a |
PEG Ratio | 3.95 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.06, with an EV/FCF ratio of 16.45.
EV / Earnings | 38.46 |
EV / Sales | 2.45 |
EV / EBITDA | 8.06 |
EV / EBIT | 16.97 |
EV / FCF | 16.45 |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.81.
Current Ratio | 1.28 |
Quick Ratio | 0.66 |
Debt / Equity | 0.81 |
Debt / EBITDA | 4.07 |
Debt / FCF | 8.28 |
Interest Coverage | 5.49 |
Financial Efficiency
Return on equity (ROE) is 4.15% and return on invested capital (ROIC) is 3.29%.
Return on Equity (ROE) | 4.15% |
Return on Assets (ROA) | 2.77% |
Return on Capital (ROIC) | 3.29% |
Revenue Per Employee | 92.25M |
Profits Per Employee | 5.88M |
Employee Count | 49,281 |
Asset Turnover | 0.31 |
Inventory Turnover | 1.31 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.90% in the last 52 weeks. The beta is 0.46, so Takeda Pharmaceutical Company's price volatility has been lower than the market average.
Beta (5Y) | 0.46 |
52-Week Price Change | -6.90% |
50-Day Moving Average | 4,147.30 |
200-Day Moving Average | 4,182.25 |
Relative Strength Index (RSI) | 32.72 |
Average Volume (20 Days) | 3,332,230 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Takeda Pharmaceutical Company had revenue of JPY 4.55 trillion and earned 290.00 billion in profits. Earnings per share was 182.01.
Revenue | 4.55T |
Gross Profit | 3.00T |
Operating Income | 653.63B |
Pretax Income | 269.71B |
Net Income | 290.00B |
EBITDA | 1.33T |
EBIT | 653.63B |
Earnings Per Share (EPS) | 182.01 |
Balance Sheet
The company has 859.02 billion in cash and 5.61 trillion in debt, giving a net cash position of -4,750.38 billion or -2,996.74 per share.
Cash & Cash Equivalents | 859.02B |
Total Debt | 5.61T |
Net Cash | -4,750.38B |
Net Cash Per Share | -2,996.74 |
Equity (Book Value) | 6.92T |
Book Value Per Share | 4,365.91 |
Working Capital | 666.78B |
Cash Flow
In the last 12 months, operating cash flow was 876.31 billion and capital expenditures -198.53 billion, giving a free cash flow of 677.78 billion.
Operating Cash Flow | 876.31B |
Capital Expenditures | -198.53B |
Free Cash Flow | 677.78B |
FCF Per Share | 427.57 |
Margins
Gross margin is 65.95%, with operating and profit margins of 14.38% and 6.38%.
Gross Margin | 65.95% |
Operating Margin | 14.38% |
Pretax Margin | 5.93% |
Profit Margin | 6.38% |
EBITDA Margin | 29.22% |
EBIT Margin | 14.38% |
FCF Margin | 14.91% |
Dividends & Yields
This stock pays an annual dividend of 196.00, which amounts to a dividend yield of 4.86%.
Dividend Per Share | 196.00 |
Dividend Yield | 4.86% |
Dividend Growth (YoY) | 4.35% |
Years of Dividend Growth | 2 |
Payout Ratio | 101.62% |
Buyback Yield | -1.07% |
Shareholder Yield | 3.79% |
Earnings Yield | 4.51% |
FCF Yield | 10.59% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Takeda Pharmaceutical Company has an Altman Z-Score of 1.17. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.17 |
Piotroski F-Score | n/a |